ArticleOncotarget2014

p53 status as effect modifier of the association between pre-treatment fasting glucose and breast cancer outcomes in non diabetic, HER2 positive patients treated with trastuzumab.

Patrizia Vici et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.